CHILDRENS HOSPITAL COLORADO
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $48.7M
- Transactions
- 4,998
- Companies
- 40
- Average per transaction
- $9,745
Who reported the payments
| Pfizer | $9,854,297 |
| Biogen | $2,277,116 |
| Vertex | $2,254,113 |
| Ultragenyx Pharmaceutical Inc. | $1,963,394 |
| Merck | $1,820,451 |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,801,130 |
| Novartis | $1,556,819 |
| AbbVie | $1,383,559 |
| Boehringer Ingelheim | $1,288,668 |
| Genentech, Inc. | $1,186,807 |
| AstraZeneca | $1,018,651 |
| Travere Therapeutics, Inc. | $1,014,458 |
| Jazz Pharmaceuticals Inc. | $992,559 |
| Amgen | $915,615 |
| Acadia Pharmaceuticals Inc | $873,569 |
| Biomarin Pharmaceutical Inc. | $837,265 |
| Rhythm Pharmaceuticals, Inc. | $835,351 |
| Eli Lilly | $637,906 |
| Ascendis Pharma Endocrinology Inc | $617,106 |
| Hoffmann-la Roche Limited | $608,829 |
| Regeneron | $605,295 |
| Sarepta Therapeutics, Inc. | $601,882 |
| Edwards Lifesciences | $584,485 |
| Teva Pharmaceuticals USA, Inc. | $528,970 |
| Janssen Research & Development, LLC | $528,698 |
| Neurocrine Biosciences, Inc. | $510,371 |
| Zealand Pharma A/s | $497,738 |
| Med-el Corporation | $465,787 |
| Biofire Diagnostics, LLC | $453,858 |
| Ionis Pharmaceuticals, Inc. | $442,218 |
| PTC Therapeutics, Inc. | $412,871 |
| Albireo Pharma, Inc. | $390,974 |
| Bristol Myers Squibb | $375,561 |
| Smith+Nephew | $371,415 |
| Medtronic | $358,245 |
| Gilead | $337,398 |
| GW Research Limited | $304,646 |
| Sumitomo Pharma America, Inc. | $303,381 |
| Soleno Therapeutics, Inc. | $300,330 |
| Immedica Pharma US, Inc. | $298,362 |